Skip to main content

Table 1 Treatment-emergent adverse events occurring in ≥5% of patients or with between-groups p <.10

From: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

 

OLZ LAI 150 (N = 140)

OLZ LAI 405 (N = 318)

OLZ LAI 300 (N = 141)

Overall p-valuea

Cochran-Armitage Test p-value

Anxiety

5 (3.57%)

17 (5.35%)

7 (4.96%)

.767

.686

Headache

7 (5.00%)

9 (2.83%)

3 (2.13%)

.355

.216

Increased appetite

1 (0.71%)

3 (0.94%)

5 (3.55%)

.080

.031

Insomnia

11 (7.86%)

23 (7.23%)

9 (6.38%)

.871

.632

Nasopharyngitis

8 (5.71%)

11 (3.46%)

7 (4.96%)

.442

.947

Schizophrenia

6 (4.29%)

3 (0.94%)

2 (1.42%)

.047

.165

Somnolence

8 (5.71%)

10 (3.14%)

5 (3.55%)

.367

.467

Weight increased

12 (8.57%)

16 (5.03%)

15 (10.64%)

.071

.267

  1. Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141).
  2. aTest of overall group differences based on Fisher's exact test.